head-neck-plastic-surgery-2017-posters-accepted-abstracts

5 / 12

Page 67
conferenceseries.com
Volume 7, Issue 3 (Suppl) Otolaryngol (Sunnyvale), an open access journal
ISSN:2161-119X Head, Neck and Plastic Surgery 2017
June 19-20, 2017
June 19-20, 2017 Philadelphia, USA
5th Global Summit and Expo on
Head, Neck and Plastic Surgery
Otolaryngol (Sunnyvale) 2017, 7:3 (Suppl)
DOI: 10.4172/2161-119X-C1-017
Ear reconstruction using the Antia-Buch principles
Osamah Al-Hayo1, Vlad Ilie, Victor Ilie2 and Mihaela Lefter2
1Nepean Hospital, Australia
2Gosford Hospital, Australia
Purpose: The reconstruction of the ear following resection of part of it especially the helix, scapha and anti-helix is a confronting
problem for plastic surgery. Many techniques had been described to approach this issue and to minimize the complications
raised from resection of tumors as well. We present our experience with ear reconstruction using chondrocutaneous flaps and
a modified Antia-Buch technique in order to obtain a more realistic result with least complications.
Methodology: The study is retrospective in design with accurate description of the ear reconstruction technique that was
performed by the same surgeon on all patients. Twenty (20) patients included in this study. The collected data included
demographics, any post-operative complications and post-operative measurements of both reconstructed and normal ears.
Results: There were no post-operative complications, all tumors were completely excised. No flap loss, wound dehiscence or
haematoma has occurred. The mean residual defect was 21.8 mm ranging from 14 mm to maximum of 30 mm in size. There
were differences noticed in height, width and projection.
Conclusion: This technique allows preservation of anatomical landmarks and contour of the ear and therefore maintaining
normal overall 3D appearance of the reconstructed ear. Reconstruction of 10 mm defects are basically allowed through this
technique with no loss in size. Due to the potential lobule distortion, we recommend applying this technique to defects up to
25 mm.
Molecular pathology of oral cancer: Clinical implications
Dhananjaya Saranath and Wendy D’Souza
SVKM’s NMIMS (Deemed to be) University, India
Oral cancer is a major health concern in India being the most common cancer in males and fifth most common cancer
females and annual incidence of 77,003 new cancer cases, contributing 26% of the global oral cancer burden. Somatic
mutations, aberrant expression, epigenomic regulation and genomic SNPs constitute specific alterations in oral cancer. The
focus of our group investigating the molecular pathology of oral cancer is on identification of predictive biomarkers to indicate
risk of oral cancer and molecular markers for early diagnosis, prognosis and as therapeutic targets. Somatic mutations in p53,
H.ras, EGF-R and NOTCH1 have been observed in 30-60% patients and epigenetic deregulation via hypermethylation in
p15/16, DAPK, MGMT, MLH1 and E-Cadherin in 36-50% patients; histone modification in H3 histone via methylation in 39-
47% and acetylation in 37-80% and miRNA deregulation in 70% oral cancer patients, providing excellent targets for specific
treatment. Several single nucleotide polymorphisms (SNPs) as genomic variants in genes associatedwith cell cycle, proliferation,
differentiation, metastasis, oxidative stress and apoptosis were examined using allelic discrimination real-time PCR assay or
high resolution melt-curve analysis. Oral cancer patients demonstrated increased risk with OR 2 to 6.73 and narrow confidence
intervals in SNPs including rs4512367 (PREX2), rs1800734 (MLH1), rs34329 (p27), rs16944 (IL1-β), rs2071214 (Survivin),
rs13026208 (GALNT13), rs3803300 (AKT1), rs187115 (CD44), rs1982073 (TGFβ), rs1229984 (ADH1B), rs187238 (IL-18)
and rs189037 (ATM). Whereas 50% decreased risk was observed with alternate genotypes in PREX2 and TGFβ. Further, the
somatic mutations in H.ras gene at codons 12/13/61 was used as a prototype target for identification of small molecules from
Maybridge Hit Finder Library, for selective inhibition of constitutive activation of H.ras and consequent proliferation of oral
cancer cells. The identified molecules may be potential single or combinatorial therapeutic agents. Thus, molecular biomarkers
of oral cancer indicate clinical applications for better management of oral cancer patients.